Deutsche Bank Ag\ Geron Corp Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Geron Corp stock. As of the latest transaction made, Deutsche Bank Ag\ holds 718,754 shares of GERN stock, worth $2.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

718,754

Previous 1,344,128 46.53%

Holding current value

$2.87 Million

Previous $5.7 Million 42.74%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$4.17 - $4.99 $2.61 Million - $3.12 Million	-625,374 Reduced 46.53%	718,754 $3.26 Million
Q2 2024 Aug 14, 2024	SELL	$3.1 - $5.09 $24,567 - $40,338	-7,925 Reduced 0.59%	1,344,128 $5.7 Million
Q1 2024 May 15, 2024	SELL	$1.75 - $3.44 $10 Million - $19.7 Million	-5,715,951 Reduced 80.87%	1,352,053 $4.46 Million
Q4 2023 Feb 14, 2024	BUY	$1.74 - $2.31 $11.9 Million - $15.8 Million	6,821,171 Added 2763.48%	7,068,004 $14.9 Million
Q3 2023 Nov 09, 2023	BUY	$2.11 - $3.28 $75,962 - $118,083	36,001 Added 17.08%	246,833 $523,000
Q2 2023 Aug 14, 2023	SELL	$1.97 - $3.69 $183,014 - $342,804	-92,901 Reduced 30.59%	210,832 $676,000
Q1 2023 May 15, 2023	BUY	$2.14 - $3.4 $159,922 - $254,082	74,730 Added 32.63%	303,733 $659,000
Q4 2022 Feb 13, 2023	BUY	$2.03 - $2.42 $152,388 - $181,664	75,068 Added 48.77%	229,003 $554,000
Q3 2022 Nov 14, 2022	SELL	$1.67 - $2.94 $104,343 - $183,694	-62,481 Reduced 28.87%	153,935 $360,000
Q2 2022 Aug 11, 2022	BUY	$1.19 - $1.65 $23,016 - $31,914	19,342 Added 9.81%	216,416 $335,000
Q1 2022 May 13, 2022	SELL	$0.99 - $1.6 $19,450 - $31,435	-19,647 Reduced 9.07%	197,074 $268,000
Q4 2021 Feb 11, 2022	BUY	$1.22 - $1.72 $7,190 - $10,137	5,894 Added 2.8%	216,721 $264,000
Q3 2021 Nov 04, 2021	SELL	$1.2 - $1.5 $25,498 - $31,873	-21,249 Reduced 9.16%	210,827 $289,000
Q2 2021 Aug 11, 2021	BUY	$1.25 - $1.83 $6,621 - $9,693	5,297 Added 2.34%	232,076 $327,000
Q1 2021 May 13, 2021	SELL	$1.52 - $2.1 $26,578 - $36,720	-17,486 Reduced 7.16%	226,779 $358,000
Q4 2020 Feb 16, 2021	BUY	$1.55 - $2.05 $82,173 - $108,680	53,015 Added 27.72%	244,265 $388,000
Q3 2020 Nov 12, 2020	BUY	$1.59 - $2.19 $100,480 - $138,397	63,195 Added 49.35%	191,250 $334,000
Q2 2020 Aug 13, 2020	BUY	$1.05 - $2.18 $73,222 - $152,024	69,736 Added 119.58%	128,055 $279,000
Q1 2020 May 14, 2020	SELL	$0.89 - $1.49 $14,050 - $23,522	-15,787 Reduced 21.3%	58,319 $69,000
Q4 2019 Feb 14, 2020	BUY	$1.27 - $1.54 $37,918 - $45,979	29,857 Added 67.47%	74,106 $100,000
Q3 2019 Nov 14, 2019	SELL	$1.15 - $1.59 $3,324 - $4,596	-2,891 Reduced 6.13%	44,249 $58,000
Q2 2019 Aug 14, 2019	SELL	$1.37 - $2.02 $214,880 - $316,830	-156,847 Reduced 76.89%	47,140 $65,000
Q1 2019 May 15, 2019	SELL	$1.01 - $1.83 $690,530 - $1.25 Million	-683,694 Reduced 77.02%	203,987 $336,000
Q4 2018 Feb 14, 2019	BUY	$0.98 - $1.85 $125,109 - $236,176	127,663 Added 16.8%	887,681 $887,000
Q3 2018 Dec 21, 2021	BUY	$1.76 - $6.38 $725,046 - $2.63 Million	411,958 Added 118.36%	760,018 $1.34 Million
Q3 2018 Nov 14, 2018	SELL	$1.76 - $6.38 $91,778 - $332,697	-52,147 Reduced 13.03%	348,060 $611,000
Q2 2018 Apr 21, 2020	BUY	$3.29 - $4.82 $264,400 - $387,359	80,365 Added 25.13%	400,207 $1.37 Million
Q2 2018 Aug 14, 2018	SELL	$3.29 - $4.82 $558,270 - $817,891	-169,687 Reduced 34.66%	319,842 $1.1 Million
Q1 2018 Oct 18, 2019	BUY	$1.81 - $5.98 $426,548 - $1.41 Million	235,662 Added 92.83%	489,529 $2.08 Million
Q1 2018 May 15, 2018	SELL	$1.81 - $5.98 $801,002 - $2.65 Million	-442,543 Reduced 63.55%	253,867 $1.08 Million
Q4 2017 Feb 14, 2018	BUY	$1.8 - $2.32 $516,562 - $665,791	286,979 Added 70.09%	696,410 $1.25 Million
Q3 2017 Nov 14, 2017	BUY	$1.99 - $2.65 $814,767 - $1.08 Million	409,431	409,431 $891,000

Others Institutions Holding GERN

# of Institutions

275

Shares Held

491M

Call Options Held

1.87M

Put Options Held

690K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account